Pharma Focus Asia
Eppendorf Bioprocess Solutions

Daiichi Sankyo Announces Clinical Research Collaboration to Evaluate DS-1062 in Combination with KEYTRUDA® (pembrolizumab) in Metastatic Non-Small Cell Lung Cancer

Saturday, May 30, 2020

Daiichi Sankyo Company, Limited  announced that it has entered into a clinical trial collaboration agreement with a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey, U.S.A., known as MSD outside the United States and Canada, to evaluate the combination of DS-1062, a TROP2 directed DXd antibody drug conjugate (ADC), and KEYTRUDA® (pembrolizumab) in patients with previously-treated advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations.

There are no TROP2 directed therapies and no ADCs currently approved for treatment of NSCLC, which frequently overexpresses the TROP2 protein.1

“Strategic research collaborations like this support our goal of developing our TROP2 directed DXd ADC in combination with immune checkpoint inhibitors to improve upon the current standard of care therapies across a wide range of NSCLC subtypes,” said Gilles Gallant, BPharm, PhD, FOPQ, Senior Vice President, Global Head, Oncology Development, Oncology R&D, Daiichi Sankyo. “We look forward to evaluating the safety and efficacy of DS-1062 in combination with KEYTRUDA as a potential combination therapy strategy to advance treatment outcomes for patients with metastatic NSCLC without mutations known to drive cancer growth.”

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACPHI Korea 2023Bora Pharmaceutical - A robust approach to analytical testing is essentialSelangor International Expo MEDIC 2023TFS - Webinar - DynaSpin™ Single-Use Centrifuge for harvest applicationsMedical Fair Thailand 2023ThermoFisher Scientific - NEW Mobile AppCPHI & PMEC China 20233rd ANNUAL COMPUTER SOFTWARE ASSURANCE 2023Pharma Regulatory Conclave 202320th Anniversary Hospitalog Asia 2023
Charles River Laboratories - Endosafe Compendial LAL Cartridge Technology